Thus, pancreatic lipase inhibition is an interesting advancement toward the development of potential therapeutic agents for obesity management and associated complications [5]. Orlistat is a well-known selective inhibitor of pancreatic lipase, but due to the unwanted gastrointestinal side effects associated with it and long-term therapy, there is a need to search for alternatives that are cost-effective and can offer therapeutic potential with reduced side effects [6]. Here, PNLIP is linked to obesity due to melanocortin 4 receptor deficiency.